Trials / Completed
CompletedNCT04381832
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 173 (actual)
- Sponsor
- Arcus Biosciences, Inc. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of etrumadenant (AB928)-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).
Conditions
- Prostatic Neoplasms, Castration-Resistant
- Androgen-Resistant Prostatic Neoplasms
- Castration Resistant Prostatic Neoplasms
- Prostatic Cancer, Castration-Resistant
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Etrumadenant | Etrumadenant is an A2aR and A2bR antagonist |
| DRUG | Zimberelimab | Zimberelimab is an anti-PD-1 antibody |
| DRUG | Quemliclustat | Quemliclustat is a Cluster of Differentiation (CD)73 Inhibitor. |
| DRUG | Enzalutamide | Enzalutamide is an androgen receptor inhibitor |
| DRUG | Docetaxel | Docetaxel is type of chemotherapy |
| DRUG | SG | Sacituzumab govitecan is an antibody-drug conjugate |
Timeline
- Start date
- 2020-07-07
- Primary completion
- 2024-08-30
- Completion
- 2024-08-30
- First posted
- 2020-05-11
- Last updated
- 2025-07-22
Locations
19 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04381832. Inclusion in this directory is not an endorsement.